Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results

Dianthus Therapeutics, Inc. /DE/

Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).
FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.
Cash $514.4M provides runway into 2028.
Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ reported the fourth quarter and full year ending December 31, 2025 results: net income $162.3 million or $4.20 per share, EPS $4.20 per share.

Period: the fourth quarter and full year ending December 31, 2025
Net income: $162.3 million or $4.20 per share
EPS: $4.20 per share
Result: reported results

Exact text from the filing

On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2025.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-26-097555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.